PharmaNews
Matthias Hipp(University Hospital Regensburg), Hans‐Michael Steffen, Axel Matzdorff(cts CaritasKlinikum Saarbrücken), Stephan Stilgenbauer(Universität Ulm), Thomas Ulshöfer, Quanli Gao(Zhengzhou University), Christoph Tapprich(Johnson & Johnson (Germany)), Stefan Schütz(Hochschule Bremerhaven), Andreas Schwarzer, Dietmar Bulenda, Bernd Gaede, Daniel Reschke(Klinikum Oldenburg), Ralf‐Dieter Hofheinz(University of Mannheim), Ursula Vehling‐Kaiser(University of Applied Sciences Landshut), Bertram Ottillinger, A Pelc, Burkhard Alkemper(Research Center Borstel - Leibniz Lung Center), Lothar R. Pilz(Heidelberg University), Christian Klein(Roche (Switzerland)), Harald‐Morten Curth, Rudolf Schmits(Saarland University), Hans Tesch, Lingdi Zhao(Zhengzhou University), Linping Xu, Matthias Hautmann, Rudolf Schlag(University of Würzburg), Yong Zhang(Ministry of Education of the People's Republic of China), Yaomei Wang(Zhengzhou University), Ling Mai, Matthew Turner, Valentin Goede(St. Marien Hospital), Wolfgang Knauf(Krankenhaus Bethanien), S. Al-Batran(Krankenhaus Nordwest), Holger Schilling, Bettina Ledig, Wei Li, Fabian Kütting(University Hospital Cologne)
Cited by 0
Related Papers
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k